Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
We will investigate the therapeutic efficacy of EEG-synchronized noninvasive repetitive transcranial magnetic stimulation (rTMS) in the early subacute phase after ischemic stroke to improve upper limb motor rehabilitation. We hypothesize that synchronization of rTMS with the phase of the ongoing sensorimotor oscillation indicating high corticospinal excitability leads to significantly stronger improvement of paretic upper limb motor function than the same rTMS protocol non-synchronized to the ongoing sensorimotor oscillation or sham stimulation.
Full description
High-frequency rTMS will be applied to the ipsilesional motor cortex in 400 bursts of 100 Hz triplets with a mean inter-burst interval of 3 s (20 min treatment duration, 1,200 pulses per day) for 5 consecutive workdays (6,000 pulses total) at a stimulus intensity of 80% of resting motor threshold, in one of three conditions/arms, followed by 40 min task-specific hand/arm-physiotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects meeting all of the following criteria will be considered for admission to the trial:
Age ≥ 18 years at the time of signing the informed consent.
Cerebral ischemia identified by brain imaging (cerebral MRI or CT) occurred 1-14 days ago.
Subject understands and voluntarily signs an informed consent document prior to any study related assessments/procedures.
Stroke has resulted in a new arm-/hand motor deficit with ≤ 50 points in the FMA-UE.
Presence of motor evoked potentials (MEPs) in the paretic hand. MEPs has to be obtained in the resting muscle
o If no MEPs can be obtained, MEP search procedure can be repeated later up to 14 days after stroke onset.
● μ-oscillation (8-12 Hz) is recordable by EEG in the ipsilesional sensorimotor cortex with a sufficient signal-to-noise ratio of at least 3 dB
● Subject is able to adhere to the study visit schedule and other protocol requirements.
Exclusion criteria
Subjects presenting with any of the following criteria will not be included in the trial:
Primary purpose
Allocation
Interventional model
Masking
144 participants in 3 patient groups
Loading...
Central trial contact
Ulf Ziemann, Prof. Dr.; Sven Poli, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal